Summary
The distribution of cis-diamminedichloroplatinum (CDDP) was studied in 23 patients undergoing surgical resection of brain tumors metastatic from lung cancer. CDDP (100mg/m2) was administered intravenously (IV) or intra-arterially (IA) at the time of surgery, and various fluids and tissues were sampled for measurement of drug concentration. Comparison of the two routes of administration disclosed that the plasma level was slightly lower after IA than after IV infusion, whereas there was no difference between the two routes in terms of drug diffusion into the brain tissue adjacent to the tumor. However, IA administration resulted in an intratumoral drug concentration twice as high as that achieved with IV infusion. The tumor:plasma and tumor: adjacent brain ratios of drug concentration after IA injection were also twice those measured after IV administration. The distribution pattern of CDDP is characteristic of water-soluble agents. All patients experienced tolerable nausea and vomiting. Creatinine clearance was moderately reduced in ten cases, but no serious renal toxicity was observed. Seizures occurred postoperatively in nine patients. Infrequent side effects were myelosupression, ototoxicity, and postoperative intracranial bleeding. All adverse effects disappeared with conservative treatment or no intervention.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kolaric K, Roth A, Jelicic I, Matkovic A: Phase II clinical trial of cis-dichlorodiammine platinum (CIS DDP) in metastatic brain tumors. J Cancer Res Clin Oncol 104: 287–293, 1983
Kapp J, Vance R: Supraophthalmic carotid infusion for recurrent gliomas: Rationale, technique, and preliminary results for cisplatin and BCNU. J Neuro-Oncol 3: 5–11, 1985
Walker RW, Allen JC: Cisplatin in the treatment of recurrent childhood primary brain tumors. J Clin Oncol 6: 62–66, 1988
Bonnen EM, Litterst CL, Smith FP: Platinum concentrations in human glioblastoma multiforme following the use of cisplatin. Cancer Treat Rep 66: 1661–1663, 1982
Stewart DJ, Leavens M, Maor M, Feun L, Luna M, Bonura J, Caprioli R, Loo TL, Benjamin RS: Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42: 2474–2479, 1982
Armand JP, Macquet JP, LeRoy AF: Cerebrospinal fluid-platinum kinetics of cisplatin in man. Cancer Treat Rep 67: 1035–1037, 1983
Shani J, Bertram J, Russell C, Dahalan R, Chen DCP, Parti R, Ahmadi J, Kempf RA, Kawada TK, Mugia J, Wolf W: Noninvasive monitoring of drug biodistribution and metabolism: Studies with intra-arterial Pt-195m-cisplatin in humans. Cancer Res 49: 1877–1881, 1989
Stewart DJ, Benjamin RS, Zimmerman S, Caprioli RM, Wallace S, Chuang V, Calvo D III, Samuels M, Bonura J, Loo TL: Clinical pharmacology of intra-arterial cis-diamminedichloroplatinum (II). Cancer Res 43: 917–920, 1983
Feun LG, Wallace S, Stewart DJ, Chuang VP, Yung WKA, Leavens ME, Burgess MA, Savaraj N, Benjamin RS, Young SE, Tang RA, Handel S, Mavligit G, Fields WS: Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 54: 794–799, 1984
Ginos JZ, Cooper AJL, Dhawan V, Rottenberg DA: [13 N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med 28: 1844–1852, 1987
Lehane DE, Bryan RN, Horowitz B, DeSantos L, Ehni G, Zubler MA, Moiel R, Rudolph L, Aldama-Leubbert A, Mahoney D, Harper R: Intra-arterial cis-platinum chemotherapy for patients with primary and metastatic brain tumors. Cancer Drug Delivery 1: 69–77, 1983
Gormley PE, Gangji D, Wood JH, Poplack DG: Pharmacokinetic study of cerebrospinal fluid penetration of cis-diamminedichloroplatinum (II). Cancer Chemother Pharmacol 5: 257–260, 1981
Shapiro WR, Voorhies RM, Hiesiger EM, Sher PB, Basler GA, Lipschutz LE: Pharmacokinetics of tumor cell exposure to [14 C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barrier in rat brain tumors: A quantitative autoradiographic study. Cancer Res 48: 694–701, 1988
Levin VA, Kabra PM, Freeman-Dove MA: Pharmacokinetics of intracarotid artery C14-BCNU in the squirrel monkey. J Neurosurg 48: 587–593, 1978
Hochberg FH, Poletti CE, Krull IS, Strauss J: Analysis and distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in biological specimens. Neurosurgery 13: 230–233, 1983
Rozencweig M, Von Hoff DD, Slavik M, Muggia FM: Cis-diamminedichloroplatinum (II) — A new anticancer drug. Ann Int Med 86: 803–812, 1977
Williams CJ, Whitehouse JMA: Cis-platinum: A new anti-cancer agent. Br Med J 1: 1689–1691, 1979
Nakagawa H, Groothuis DR, Owens ES, Fenstermacher JD, Patlak CS, Blasberg RG: Dexamethasone effects on [125I]albumin distribution in experimental RG-2 gliomas and adjacent brain. J Cereb Blood Flow Metab 7: 687–701, 1987
Nakagawa H, Groothuis DR, Owens ES, Patlak CS, Pettigrew KD, Blasberg RG: Dexamethasone effects on vascular volume and tissue hematocrit in experimental RG-2 gliomas and adjacent brain. J Neuro-Oncol 6: 157–168, 1988
Wiltshaw E, Kroner T: Phase II study of cis-diamminedi-chloroplatinum (II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat Rep 60: 55–60, 1976
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakagawa, H., Fujita, T., Izumoto, S. et al. Cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancer. J Neuro-Oncol 16, 61–67 (1993). https://doi.org/10.1007/BF01324836
Issue Date:
DOI: https://doi.org/10.1007/BF01324836